Skip to main content

Craig Adam R's Form 4 filing

Cti Biopharma Corp (CTIC) · filed Jan 3, 2023

Accession no.
0000891293-23-000002
Filed
Jan 3, 2023
Trade date
Dec 29, 2022-Jan 3, 2023
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 5 derivative transactions. Open-market sales total $694.4K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Craig Adam RCIK 0001339498Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 29, 2022common stockMOption exerciseAcquired+13,800$0.84+$11,59241,661Direct
Dec 29, 2022common stockSSaleDisposed−13,800$6.00−$82,80027,861Direct
Dec 30, 2022common stockAGrant or awardAcquired+1,579$5.11+$8,068.6929,440Direct
Dec 30, 2022common stockMOption exerciseAcquired+12,000$0.84+$10,08041,440Direct
Dec 30, 2022common stockSSaleDisposed−12,000$6.00−$72,00029,440Direct
Dec 30, 2022common stockMOption exerciseAcquired+700$0.84+$58830,140Direct
Dec 30, 2022common stockSSaleDisposed−700$6.01−$4,20729,440Direct
Dec 30, 2022common stockMOption exerciseAcquired+4,400$0.84+$3,69633,840Direct
Dec 30, 2022common stockSSaleDisposed−4,400$6.01−$26,44429,440Direct
Jan 3, 2023common stockMOption exerciseAcquired+84,683$0.84+$71,133.72114,123Direct
Jan 3, 2023common stockSSaleDisposed−84,683$6.01F3−$508,944.8329,440Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 29, 2022Common StockMOption exerciseDisposed−13,800$0.00$0657,154Direct
Dec 30, 2022Common StockMOption exerciseDisposed−12,000$0.00$0645,154Direct
Dec 30, 2022Common StockMOption exerciseDisposed−700$0.00$0644,454Direct
Dec 30, 2022Common StockMOption exerciseDisposed−4,400$0.00$0640,054Direct
Jan 3, 2023Common StockMOption exerciseDisposed−84,683$0.00$0555,371Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)